News

In-depth Analyses of Racism and Greater Recruitment of Black Practitioners Needed to Address Inequities in Mental Health Treatment for Black Americans

by

NEW YORK, Dec. 14, 2023 /PRNewswire/ — A series of literature reviews publishing online December 13 in The Lancet Psychiatry journal highlight the large body of evidence on the role played by racism in mental health disparities experienced by Black people living in the United States.  Along with an essay from Black Americans that describes their lived … Read more

LIFEbeat The Music Industry Fights AIDS TO BECOME A PROGRAM OF THE ELIZABETH TAYLOR AIDS FOUNDATION

by

LOS ANGELES, Dec. 13, 2023 /PRNewswire/ — The Elizabeth Taylor AIDS Foundation (ETAF) announced today that LIFEbeat will become a program of The Elizabeth Taylor AIDS Foundation. LIFEbeat mobilizes the music and entertainment industry to provide sexual health resources, including HIV, at music tours, special events, with broadcast, social media, and print campaigns. LIFEbeat engages … Read more

Drive Safely on Washington Roads this Holiday Season

by

Enhanced patrols on roads and highways begin December 13 OLYMPIA, Wash., Dec. 12, 2023 /PRNewswire-PRWeb/ — The Washington Traffic Safety Commission (WTSC) is asking Washingtonians to have a happy holiday season by travelling safely and responsibly on all roads and highways. Law enforcement agencies across the state will have an increased presence on roads over … Read more

Where Style Meets Precision in Ovulation Tracking

by

PRINCETON, N.J., Dec. 12, 2023 /PRNewswire/ — In a groundbreaking advancement within women’s health technology, the Femometer Smart Ring has emerged as a trailblazer, reshaping the landscape of basal body temperature tracking, fertility awareness for conception and overall well-being. In May 2023, Jordyn had the exciting opportunity to be one of the initial trial users … Read more

Studies Highlight Both Novel Treatments and Enduring Value of Older Approaches

by

 Findings suggest “less is more” and “tried and true” may benefit select patients SAN DIEGO, Dec. 10, 2023 /PRNewswire/ — Research findings being presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition highlight new treatment approaches that are enabling patients to live longer or better, judicious uses of older treatment approaches, … Read more

InvaGen Pharmaceuticals Issues Voluntary Nationwide Recall of Vigabatrin for Oral Solution, USP 500mg due to Leaking Sachets

by

HAUPPAUGE, N.Y., Dec. 9, 2023 /PRNewswire/ — Cipla Limited today announced that its wholly-owned subsidiary, InvaGen Pharmaceuticals Inc. is voluntarily recalling one lot of Vigabatrin for Oral Solution, USP 500mg, to the consumer level. Vigabatrin for Oral Solution, USP 500 mg has been found to have seal integrity issues allowing for powder leakage from the … Read more

REAGILA: An Atypical Antipsychotic Used in the Treatment of Schizophrenia and Manic or Mixed Episodes of Bipolar Disorder

by

DUBLIN, Dec. 8, 2023 /PRNewswire/ — The “REAGILA Drug Insight and Market Forecast – 2032” drug pipelines has been added to  ResearchAndMarkets.com’s offering. This report provides comprehensive insights about REAGILA for schizophrenia in the seven major markets. A detailed picture of the REAGILA for schizophrenia in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and … Read more

Saffron Market size to grow by USD 210.37 million from 2022 to 2027, Driven by the growing use in the pharmaceutical and cosmetics industries

by

NEW YORK, Dec. 8, 2023 /PRNewswire/ — The saffron market size is set to grow by USD 210.37 million between 2022 and 2027 and register a CAGR of 8.1%, according to Technavio’s latest market research report. With a focus on identifying dominant industry influencers, Technavio’s reports present a detailed study by the way of synthesis, and … Read more

University of Maryland and BioGenCell Announce the Launch of BioGenCell Fifth Chronic Limb-Threatening Ischemia Clinical Trial Site in the United States

by

BioGenCell has announced the inauguration of the fifth Phase II cell-therapy-based clinical trial site for Chronic Limb-Threatening Ischemia (CLTI) in the United States at the University of Maryland, Baltimore. This initiative is committed to dramatically reducing the incidence of amputations in patients afflicted with severe CLTI. BALTIMORE, Dec. 7, 2023 /PRNewswire/ — BioGenCell, a pioneer … Read more